Piramal Pharma LimitedNSE: PPLPHARMA

Press Release Nov 05 2025

· Issued by Piramal Pharma Limited

Filed with NSE · · 25 pages · English

Summary by 6ix AI

The report highlights a decline in revenue growth due to inventory destocking by a customer in a significant contract development and manufacturing order. Despite lower revenues, the company managed to reduce its net debt and maintain a stable EBITDA margin through cost optimization efforts.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Piramal Pharma Limited on 6ix

In the deck

Earlier from Piramal Pharma

Later from Piramal Pharma

All Piramal Pharma news releases